Intended use:

RIDASCREEN® Anti-IFX Antibodies is an enzyme linked immunoassay intended for the quantitative determination of antibodies to infliximab (ATI) in human serum and plasma.

Key features

  • CE-marked versions of the ELISA tests of KU Leuven
  • Highly specific antibodies
  • Validated in clinical trials
  • Validated on automated ELISA readers (e.g. DSX®)

Therapeutic Drug Monitoring
Infliximab (IFX) is a chimeric antibody that targets the pro-inflammatory cytokine TNF-alpha. The introduction of infliximab has revolutionized the treatment of chronic inflammatory diseases like inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and spondyloarthritis. It has been shown that infliximab can induce deep remission and improve the patient’s quality of life. Some patients do not respond to infliximab therapy upon induction (primary non-responders), while others lose response over time (secondary non-responders).


Secondary loss of response is often due to the development of anti-infliximab antibodies (ATI), because of the immunogenic character of the drug. ATI can develop in any patient undergoing infliximab therapy and are primarily neutralizing the activity of infliximab through immunocomplex formation. In addition, these immunocomplexes are rapidly cleared from the system. Analytically, they are responsible for subtherapeutic infliximab concentrations. Therefore, in the case of very low trough concentrations of infliximab (< 1 μg/ml), subsequent measurement of ATI may be helpful to determine the optimal treatment strategy.

Diagnostic Value

The diagnostic value of the RIDASCREEN® Anti-IFX Antibodies lies in its ability to stratify patients with subtherapeutic infliximab concentrations (< 1 µg/ml) in patients who need dose intensification or a drug (class) switch. Patients with low infliximab concentrations (< 1 µg/ml) and low ATI titers can benefit from infliximab dose intensification, as shown in several studies. However, the ATI titer of patients with low ATI titers undergoing a dose intensified treatment regimen must be adequately monitored. Patients that have high ATI titers are preferably switched to another drug, both within class or out of class.

Single Components:

Art. No. G09042
Test format Microtiterplate with 96 wells (12 strips with 8 breakable wells each)
Incubation time 2h 45 min
External link I TDM Checker

Dear customers,

we have started to provide the documents for our products in an electronic format. These are the Instructions for Use (IFU), the Safety Data Sheets (SDS) and the Certificate of Analysis (CoA). For batches placed on the market after 01 January 2023, you can find our documents on the eIFU portal

Similar products
The RIDASCREEN® UST Monitoring is an enzyme linked immunosorbent assay intended for the quantitative determination of ustekinumab (UST, Stelara®) i...
RIDASCREEN® GLM Monitoring is an enzyme linked immunoassay intended for the quantitative determination of golimumab (GLM, Simponi®) in human serum ...
RIDA®QUICK ADM Monitoring Control Set
RIDA®QUICK ADM Monitoring C...
For in vitro diagnostic use. The RIDA®QUICK ADM Monitoring Control Set is intended for the use with the corresponding, batch specific kit RIDA®QUIC...

Start typing and press Enter to search